[1] |
Committee of Integrated Rehabilitation for Urogenital Tumors, Chinese Anti-Cancer Association.
Chinese expert consensus on perioperative integrated rehabilitation for radical prostatectomy (2024 edition)
[J]. China Oncology, 2024, 34(9): 890-902.
|
[2] |
PAN Jian, YE Dingwei, ZHU Yao, WANG Beihe.
Correlation analysis of PSMA PET/CT-derived parameters and circulating tumor DNA features in patients with hormone-sensitive prostate cancer
[J]. China Oncology, 2024, 34(7): 680-685.
|
[3] |
Cancer Nuclear Medicine Committee of China Anti-Cancer Association, Chinese Association of Nuclear Medicine Physicians.
Expert consensus of 177Lu-labeled PSMA radioligand therapy for clinical practice of prostate cancer (2024 edition)
[J]. China Oncology, 2024, 34(7): 702-714.
|
[4] |
PAN Jian, ZHU Yao, DAI Bo, YE Dingwei.
Advances in basic research, clinical diagnosis and treatment of prostate cancer in 2022
[J]. China Oncology, 2023, 33(3): 210-217.
|
[5] |
Society of Male Reproductive System Oncology, China Anti-Cancer Association.
Expert consensus on perioperative comprehensive treatment for high risk prostate cancer (2023 edition)
[J]. China Oncology, 2023, 33(12): 1204-1214.
|
[6] |
YANG Wenbo, ZHANG Bin, WU Jiahui, CUI Jie.
Current status and treatment direction of the immune microenvironment of castration-resistant prostate cancer
[J]. China Oncology, 2023, 33(10): 945-953.
|
[7] |
ZHOU Shukui, ZHANG Dongliang, WANG Xiang, LIU Lei, LI Zeng, YANG Shengke, LIAO Hong.
Developing a new animal model of subcutaneous transplanted prostate cancer with cell sheet technology
[J]. China Oncology, 2022, 32(3): 200-206.
|
[8] |
ZHOU Bingni, LIU Xiaohang, GU Bingxin, ZHOU Liangping, GU Yajia.
The value of mpMRI combined with 99mTc-PSMA SPECT/CT in the detection of significant residual prostate cancer after neoadjuvant androgen deprivation therapy
[J]. China Oncology, 2022, 32(2): 134-141.
|
[9] |
Chinese Prostate Cancer Consortium (CPCC), YE Dingwei, HUANG Jian.
Chinese Prostate Cancer Consortium (CPCC) Chinese expert consensus on advanced prostate cancer: clinical management of patients with metastatic hormone-sensitive prostate cancer treated by initial novel hormone therapy (2022 edition)
[J]. China Oncology, 2022, 32(12): 1242-1258.
|
[10] |
XU Wenhao, TIAN Xi, Aihetaimujiang·Anwaier , QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei.
A systematic review of current advancements of artificial intelligence in genitourinary cancers
[J]. China Oncology, 2022, 32(1): 68-74.
|
[11] |
WEI Yu , ZHANG Tingwei , HE Yi , LI Jun , BI Jianbin , ZENG Yu , WAN Lijun , WU Gaoliang , WANG Huansheng , ZHANG Jun , ZHU Wei , QU Yuanyuan , ZHU Yao , YE Dingwei .
Preliminary study on efficacy and safety of fluzoparib in patients with metastatic castration-resistant prostate cancer
[J]. China Oncology, 2021, 31(7): 561-566.
|
[12] |
CAO Dalong, ZHU Wenkai, SHI Guohai, ZHANG Hailiang, WANG Ziliang, YE Dingwei.
The influence of PRUNE2 gene point mutation on proliferation, apoptosis, invasion and migration of prostate cancer DU145 cells
[J]. China Oncology, 2021, 31(6): 441-446.
|
[13] |
WANG Zhu, ZHANG Ying, ZHANG Jianwen, DENG Qiong, LIANG Hui.
Nuclear receptor HNF4α promotes castration-resistant prostate cancer via its regulation of androgen receptor expression
[J]. China Oncology, 2021, 31(3): 170-175.
|
[14] |
BIAN Xiaojie, YE Dingwei.
New ideas of androgen deprivation therapy for prostate cancer: new progress in clinical research of testosterone maximum control
[J]. China Oncology, 2021, 31(12): 1209-1214.
|
[15] |
PAN Jian, WEI Yu, YE Dingwei, ZHU Yao.
Correlation between EGFR (rs884419) gene polymorphism and clinicopathological characteristics of prostate cancer
[J]. China Oncology, 2021, 31(11): 1104-1109.
|